Skip to main content
null
Clinical Hematology International
  • Menu
  • Articles
    • Case Report
    • Case study
    • Correspondence
    • Editorial
    • General
    • Original Research Articles
    • Perspective Article
    • Research Articles
    • Retrospective study
    • Review Articles
    • Survey
    • Systematic Reviews
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Blog
  • Conference-Event-Webinar
  • search

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:43223/feed
General
Vol. 4, Issue 3, 2022August 09, 2022 BST

High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens

Katrine Fladeland Iversen, Line Nederby, Thomas Lund, Torben Plesner,
CancerCOVID-19PediatricsOncologyHematology
https://doi.org/10.1007/s44228-022-00013-7
Clinical Hematology International
Iversen, Katrine Fladeland, Line Nederby, Thomas Lund, and Torben Plesner. 2022. “High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens.” Clinical Hematology International 4 (3): 107–16. https:/​/​doi.org/​10.1007/​s44228-022-00013-7.
Save article as...▾

View more stats

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Powered by Scholastica, the modern academic journal management system